Autres langues Newbury Pharmaceuticals AB

Actions

NEWBRY

SE0015244884

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
3,22 ^SEK	-3,01%		+0,62%	+4,89%

20/06	Newbury Pharmaceuticals obtient l'approbation générique pour le stylo pré-rempli de Liraglutide	CI
10/04	Newbury Pharmaceuticals AB (publ) publie ses résultats pour le deuxième trimestre et le semestre clos le 29 février 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	20/06
Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen	20/06
Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder	18/06
Newbury Pharmaceuticals Q2 - A bump in the road	11/04
Newbury Pharmaceuticals interim report September 2023 – February 2024	10/04
Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	10/04
Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 19 million	04/03
Newbury Pharmaceuticals Secures SEK9 Million Sales Order	22/02
Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK	22/02
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million	22/02
Nintedanib Newbury approved by the Swedish Health Authorities	17/01
Newbury Pharmaceuticals Q1 Report - Ramp-up in sales	11/01
ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB	10/01
Newbury Pharmaceuticals interim report September 2023 – November 2023	10/01
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023	10/01
Newbury Pharmaceuticals publishes its annual report for 2022/2023	13/12
Kallelse till årsstämma i Newbury Pharmaceuticals AB	08/12
Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg	20/10/23
Newbury Pharmaceuticals Q4 Report - Bolstered business	12/10/23
Newbury Pharmaceuticals year-end report September 2022 – August 2023	11/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Newbury Pharmaceuticals AB

Actions

NEWBRY

SE0015244884

Autres langues

Filtres